Previous 10 | Next 10 |
New 3D structure generation functionality and extensions to the HTPK Simulation Module among the many enhancements Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical and biotechnology industries, today ann...
FDA Renewal Ensures Access for DILIsym Evaluation of Drug Candidate Submissions Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that the U.S. Food and Drug A...
Collaboration with the US FDA and Center for Research on Complex Generics to Establish the Suitability of Model-Integrated Evidence to Demonstrate Bioequivalence for Long-Acting Injectables Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulati...
Simulations Plus (NASDAQ:SLP) has declared $0.06/share quarterly dividend, in line with previous. Payable May 2; for shareholders of record April 25; ex-div April 22. See SLP Dividend Scorecard, Yield Chart, & Dividend Growth. For further details see: Simulations Plus goes ex d...
Simulations Plus (NASDAQ:SLP) announces a new funded collaboration with a large pharmaceutical company to expand and validate the mechanistic in vitro dissolution models for intravitreal injectable formulations within the DDDPlus software. James Mullin, Senior Principal Sc...
Funded partnership with large pharmaceutical company will enhance mechanistic dissolution models for injectable formulations Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and...
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that management will be participating in the Berenberg Discover AI Seminar at The Newbury Boston in Boston, Massachusetts, on...
Image source: The Motley Fool. Simulations Plus, Inc. (NASDAQ: SLP) Q2 2022 Earnings Call Apr 06, 2022 , 5:00 p.m. ET Operator Continue reading For further details see: Simulations Plus, Inc. (SLP) Q2 2022 Earnings Call Transcript
Simulations Plus, Inc. (SLP) Q2 2022 Earnings Conference Call April 06, 2022 05:00 PM ET Company Participants Brian Siegel - Hayden IR Shawn O'Connor - Chief Executive Officer Will Frederick - Chief Financial Officer Conference Call Participants Francois Brisebois - Oppenheimer Lucas Baranows...
The following slide deck was published by Simulations Plus, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Simulations Plus, Inc. 2022 Q2 - Results - Earnings Call Presentation
News, Short Squeeze, Breakout and More Instantly...
Objective to define best practices for the use of novel PBK modeling strategies to support animal-free safety assessment of new chemicals Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance an...
Total revenue of $18.5 million and diluted earnings per share (EPS) of $0.15 Maintains full-year revenue guidance of $69 to $72 million and updates EPS guidance Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulati...
2024-06-24 16:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...